Results 1 to 10 of about 45,197 (186)

Poly (ADP-ribose) polymerase inhibitors in cancer therapy. [PDF]

Chin Med J (Engl)
. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death ...
Zhu Z, Shi Y.
europepmc   +2 more sources

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer. [PDF]

Front Pharmacol, 2023
Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair.
Dong R, Ding T, Li Z.
europepmc   +2 more sources

Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. [PDF]

Rev Cardiovasc Med
The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including ...
Ma J, Li C, Wang W, Fan X, Wei T, Ma X, Wang Y, Feng C, Yu J.   +8 more
europepmc   +2 more sources

Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. [PDF]

Haematologica
Not available.
Cannova JM, Battaglia MR, Roloff GW, Cetin S, Tallarico M, Stock W, Patel AA, Odenike O, Larson RA, Thirman MJ, Nawas MT, Wang P, Tjota MY, Segal JP, Venkataraman G, DuVall AS, Drazer MW.   +16 more
europepmc   +2 more sources

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

Women's Health, 2018
There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and ...
Maurie Markman
exaly   +2 more sources

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

Therapeutic Advances in Medical Oncology, 2011
The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi).
Nicola Curtin
exaly   +2 more sources

R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP-Ribose) Polymerase Inhibitors. [PDF]

Bioinform Biol Insights
An advanced graph neural network (GNN) is of great promise to facilitate predicting Poly ADPribose polymerase inhibitors (PARPi). Recent studies design models by leveraging graph representations and molecular descriptor representations, unfortunately ...
Zonyfar C, Njimbouom SN, Mosalla S, Kim JD.   +3 more
europepmc   +2 more sources

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

Journal of Medical Case Reports, 2021
Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer.
Rosa Montero-Macias, Meriem Koual, Céline Crespel, Marie Aude Le Frére-Belda, Hélène Blons Hélène, Huyen-Thu Nguyen-Xuan, Simon Garinet, Géraldine Perkins, Vincent Balay, Catherine Durdux, Marie Florin, Hélène Péré, Anne-Sophie Bats   +12 more
doaj   +1 more source

Pyridazine Based Compounds with PARP-1 Inhibitory Activity

Archives of Pharmaceutical Sciences Ain Shams University, 2023
Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman, Mai Y. Jaballah, Ahmed A. Al-Karmalawy , Khaled A. M. Abouzid   +3 more
doaj   +1 more source

The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer

Nowotwory, 2022
Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells ...
Katarzyna Zubik, Julia Talaśka, Dawid Sigorski, Sergiusz Nawrocki   +3 more
doaj   +1 more source